We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The funding supports Inovio’s large-scale production of devices to deliver potentially hundreds of millions of doses of its vaccine next year, the company said. Read More
Gilead Sciences has gotten approval from the FDA to launch a phase 1 trial of an inhaled version of its antiviral remdesivir for the earlier treatment of COVID-19 patients. Read More
Ridgeback Biotherapeutics in July will launch two phase 2 trials of its investigational antiviral EIDD-2801 as a potential COVID-19 treatment. Read More
Former FDA Chief Scientist Jesse Goodman told a House subcommittee hearing that the FDA’s decision to allow diagnostic test developers to self-validate their COVID-19 products caused a flood of unqualified products on the market. Read More
A European Union-backed research consortium has identified raloxifene, an osteoporosis drug, as a possible treatment for mildly symptomatic COVID-19 patients. Read More
Chinese drugmaker Clover Biopharmaceuticals has dosed the first participants in a phase 1 trial of its COVID-19 vaccine candidate, an Australian study that’s also evaluating two adjuvants contributed by its research partners. Read More
The UK government’s decision to ban the export of dexamethasone, the inexpensive anti-inflammatory drug that’s shown promise as a COVID-19 treatment, is getting pushback from within the country. Read More
RSS
